| 0.796 | 0.003 | 0.796 | Anesthetic local | | |
| 0.536 | 0.016 | 0.536 | Calcium channel L-type activator | | |
| 0.421 | 0.006 | 0.421 | Nav1.2 sodium channel blocker | | |
| 0.423 | 0.019 | 0.423 | Psychostimulant | | |
| 0.403 | 0.005 | 0.403 | Nav1.3 sodium channel blocker | | |
| 0.444 | 0.086 | 0.444 | Caspase 9 stimulant | | |
| 0.357 | 0.023 | 0.357 | Anesthetic general | | |
| 0.334 | 0.015 | 0.334 | Gastrin inhibitor | | |
| 0.32 | 0.028 | 0.32 | Ca(v)3.3 blocker | | |
| 0.312 | 0.037 | 0.312 | Sigma receptor agonist | | |
| 0.302 | 0.029 | 0.302 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.379 | 0.12 | 0.379 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | | |
| 0.273 | 0.019 | 0.273 | Antipruritic | | |
| 0.24 | 0.004 | 0.24 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.294 | 0.059 | 0.294 | Transcription factor STAT inhibitor | | |
| 0.238 | 0.004 | 0.238 | Sphingosine 1-phosphate receptor 2 antagonist | | |
| 0.236 | 0.011 | 0.236 | Nav1.6 sodium channel blocker | | |
| 0.338 | 0.115 | 0.338 | Analgesic | | |
| 0.277 | 0.061 | 0.277 | Interleukin agonist | | |
| 0.277 | 0.065 | 0.277 | Transcription factor STAT3 inhibitor | | |
| 0.216 | 0.014 | 0.216 | Falcipain 3 inhibitor | | |
| 0.279 | 0.079 | 0.279 | Spasmolytic | | |
| 0.292 | 0.094 | 0.292 | Vasodilator, coronary | | |
| 0.205 | 0.008 | 0.205 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.268 | 0.08 | 0.268 | Insulysin inhibitor | | |
| 0.288 | 0.104 | 0.288 | Calcium channel activator | | |
| 0.237 | 0.062 | 0.237 | Anticonvulsant | | |
| 0.315 | 0.149 | 0.315 | 5 Hydroxytryptamine release inhibitor | | |
| 0.241 | 0.077 | 0.241 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.202 | 0.042 | 0.202 | Acetylcholine M1 receptor antagonist | | |
| 0.192 | 0.031 | 0.192 | Neurotrophic factor | | |
| 0.196 | 0.037 | 0.196 | Neurotensin receptor agonist | | |
| 0.227 | 0.08 | 0.227 | Neuropeptide Y2 antagonist | | |
| 0.152 | 0.005 | 0.152 | Acetyl-CoA transferase inhibitor | | |
| 0.148 | 0.004 | 0.148 | Sphingosine kinase inhibitor | | |
| 0.275 | 0.134 | 0.275 | GABA C receptor rho-3 antagonist | | |
| 0.233 | 0.094 | 0.233 | Cardiotonic | | |
| 0.259 | 0.119 | 0.259 | Antithrombotic | | |
| 0.15 | 0.013 | 0.15 | Cannabinoid receptor agonist | | |
| 0.162 | 0.029 | 0.162 | Nav1.1 sodium channel blocker | | |
| 0.269 | 0.136 | 0.269 | Calpain 2 inhibitor | | |
| 0.277 | 0.145 | 0.277 | Beta lactamase inhibitor | | |
| 0.147 | 0.023 | 0.147 | Prolactin inhibitor | | |
| 0.128 | 0.006 | 0.128 | CC chemokine 5 receptor agonist | | |
| 0.124 | 0.004 | 0.124 | Sphingosine kinase 1 inhibitor | | |
| 0.133 | 0.012 | 0.133 | Nicotinic alpha4beta2 receptor antagonist | | |
| 0.218 | 0.099 | 0.218 | Superoxide dismutase inhibitor | | |
| 0.259 | 0.141 | 0.259 | Immunosuppressant | | |
| 0.126 | 0.011 | 0.126 | Sphingosine 1-phosphate receptor antagonist | | |
| 0.122 | 0.014 | 0.122 | Cannabinoid CB2 receptor agonist | | |
| 0.112 | 0.005 | 0.112 | Potassium channel (Tandem pore domain) blocker | | |
| 0.141 | 0.035 | 0.141 | Caspase 3 inhibitor | | |
| 0.12 | 0.014 | 0.12 | Cannabinoid CB1 receptor agonist | | |
| 0.209 | 0.105 | 0.209 | Calpain inhibitor | | |
| 0.212 | 0.112 | 0.212 | 5 Hydroxytryptamine release stimulant | | |
| 0.107 | 0.008 | 0.107 | Sphingosine 1-phosphate receptor 1 antagonist | | |
| 0.237 | 0.138 | 0.237 | Vasodilator, peripheral | | |
| 0.23 | 0.132 | 0.23 | Thyroid hormone beta antagonist | | |
| 0.15 | 0.052 | 0.15 | Cholinergic antagonist | | |
| 0.147 | 0.052 | 0.147 | Acetylcholine antagonist | | |
| 0.123 | 0.029 | 0.123 | Acetylcholine nicotinic antagonist | | |
| 0.099 | 0.008 | 0.099 | Sphingosine kinase 2 inhibitor | | |
| 0.152 | 0.061 | 0.152 | Neuropeptide Y1 antagonist | | |
| 0.132 | 0.043 | 0.132 | Nav1.4 sodium channel blocker | | |
| 0.13 | 0.043 | 0.13 | Transcription factor STAT6 inhibitor | | |
| 0.224 | 0.141 | 0.224 | Thyroid hormone antagonist | | |
| 0.135 | 0.054 | 0.135 | Acetylcholine muscarinic antagonist | | |
| 0.131 | 0.051 | 0.131 | Calcium channel N-type blocker | | |
| 0.183 | 0.104 | 0.183 | Potassium channel blocker | | |
| 0.226 | 0.148 | 0.226 | Interleukin 2 agonist | | |
| 0.078 | 0.005 | 0.078 | Acetyl-CoA transferase 1 inhibitor | | |
| 0.134 | 0.065 | 0.134 | Toll-Like receptor 2 antagonist | | |
| 0.083 | 0.015 | 0.083 | Sphingosine 1-phosphate receptor 3 antagonist | | |
| 0.08 | 0.013 | 0.08 | Nicotinic receptor alpha3 subunit antagonist | | |
| 0.084 | 0.017 | 0.084 | Enoyl-[acyl-carrier-protein] reductase inhibitor | | |
| 0.079 | 0.013 | 0.079 | Nicotinic alpha3beta2 receptor antagonist | | |
| 0.136 | 0.072 | 0.136 | Calcium channel blocker | | |
| 0.091 | 0.028 | 0.091 | Neuronal nicotinic receptor antagonist | | |
| 0.095 | 0.033 | 0.095 | Interferon agonist | | |
| 0.074 | 0.013 | 0.074 | Prolyl endopeptidase inhibitor | | |
| 0.145 | 0.085 | 0.145 | Anticoagulant | | |
| 0.187 | 0.129 | 0.187 | Immunostimulant | | |
| 0.092 | 0.035 | 0.092 | Acetylcholine M4 receptor antagonist | | |
| 0.062 | 0.006 | 0.062 | Peptide deformylase inhibitor | | |
| 0.059 | 0.005 | 0.059 | Baculoviral IAP repeat-containing protein inhibitor | | |
| 0.073 | 0.019 | 0.073 | Prolactin release inhibitor | | |
| 0.082 | 0.031 | 0.082 | Phospholipase D inhibitor | | |
| 0.137 | 0.086 | 0.137 | Heat shock protein 70 antagonist | | |
| 0.077 | 0.027 | 0.077 | Interferon inducer | | |
| 0.054 | 0.004 | 0.054 | Adenosine uptake inhibitor | | |
| 0.07 | 0.022 | 0.07 | Glucosylceramidase inhibitor | | |
| 0.097 | 0.049 | 0.097 | Acetylcholine agonist | | |
| 0.136 | 0.089 | 0.136 | Ca2+-transporting ATPase inhibitor | | |
| 0.072 | 0.026 | 0.072 | Calcium channel T-type blocker | | |
| 0.053 | 0.008 | 0.053 | Prostaglandin EP4 antagonist | | |
| 0.109 | 0.066 | 0.109 | 5 Hydroxytryptamine 3A agonist | | |
| 0.1 | 0.057 | 0.1 | Interleukin 1 beta converting enzyme inhibitor | | |
| 0.111 | 0.069 | 0.111 | Calcium channel (voltage-sensitive) blocker | | |
| 0.118 | 0.078 | 0.118 | Cathepsin H inhibitor | | |
| 0.093 | 0.054 | 0.093 | Opioid antagonist | | |
| 0.197 | 0.158 | 0.197 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.073 | 0.034 | 0.073 | Acetylcholine M2 receptor antagonist | | |
| 0.099 | 0.061 | 0.099 | Glutamate (mGluR7) agonist | | |
| 0.057 | 0.021 | 0.057 | CC chemokine 3 receptor antagonist | | |
| 0.088 | 0.053 | 0.088 | Hematopoietic | | |
| 0.057 | 0.024 | 0.057 | HCV NS3/NS4A protease inhibitor | | |
| 0.067 | 0.034 | 0.067 | Acetylcholine M5 receptor antagonist | | |
| 0.066 | 0.034 | 0.066 | Bombesin 1 receptor agonist | | |
| 0.127 | 0.097 | 0.127 | Diuretic | | |
| 0.056 | 0.027 | 0.056 | Potassium channel (Inward rectifier) blocker | | |
| 0.052 | 0.024 | 0.052 | Dopamine D5 antagonist | | |
| 0.085 | 0.059 | 0.085 | Calcium antagonist | | |
| 0.058 | 0.031 | 0.058 | Nicotinic receptor alpha7 subunit antagonist | | |
| 0.041 | 0.016 | 0.041 | Ceramide glucosyltransferase inhibitor | | |
| 0.043 | 0.018 | 0.043 | Glucose-6-phosphate dehydrogenase inhibitor | | |
| 0.058 | 0.034 | 0.058 | 5 Hydroxytryptamine 7 agonist | | |
| 0.093 | 0.068 | 0.093 | Sphingomyelinase inhibitor | | |
| 0.038 | 0.013 | 0.038 | Epoxide hydrolase 1 inhibitor | | |
| 0.034 | 0.01 | 0.034 | Baculoviral IAP repeat-containing protein 4 inhibitor | | |
| 0.155 | 0.132 | 0.155 | Hypolipemic | | |
| 0.042 | 0.019 | 0.042 | Delayed rectifier potassium channel blocker | | |
| 0.082 | 0.06 | 0.082 | Histamine H2 receptor antagonist | | |
| 0.167 | 0.145 | 0.167 | 5 Hydroxytryptamine 3E antagonist | | |
| 0.065 | 0.043 | 0.065 | 5 Hydroxytryptamine 1D antagonist | | |
| 0.063 | 0.042 | 0.063 | Histone deacetylase SIRT3 inhibitor | | |
| 0.026 | 0.005 | 0.026 | Baculoviral IAP repeat-containing protein 3 inhibitor | | |
| 0.102 | 0.083 | 0.102 | Acetylcholine release stimulant | | |
| 0.082 | 0.064 | 0.082 | Histamine N-methyltransferase inhibitor | | |
| 0.087 | 0.068 | 0.087 | Antihistaminic | | |
| 0.049 | 0.031 | 0.049 | Cytokine production stimulant | | |
| 0.052 | 0.034 | 0.052 | Chemokine receptor agonist | | |
| 0.07 | 0.053 | 0.07 | Aminopeptidase I inhibitor | | |
| 0.07 | 0.053 | 0.07 | Cathepsin G inhibitor | | |
| 0.044 | 0.026 | 0.044 | Histone deacetylase 8 inhibitor | | |
| 0.056 | 0.039 | 0.056 | Acetyl-CoA transferase 2 inhibitor | | |
| 0.052 | 0.035 | 0.052 | 5 Hydroxytryptamine 4 antagonist | | |
| 0.052 | 0.035 | 0.052 | Cannabinoid CB2 receptor antagonist | | |
| 0.051 | 0.034 | 0.051 | Sigma receptor antagonist | | |
| 0.113 | 0.097 | 0.113 | Toll-Like receptor antagonist | | |
| 0.124 | 0.108 | 0.124 | Thiol protease inhibitor | | |
| 0.07 | 0.055 | 0.07 | Thrombin inhibitor | | |
| 0.026 | 0.012 | 0.026 | 5 Hydroxytryptamine 4 agonist | | |
| 0.052 | 0.039 | 0.052 | Alpha-mannosidase inhibitor | | |
| 0.075 | 0.063 | 0.075 | Acetylcholine nicotinic agonist | | |
| 0.043 | 0.031 | 0.043 | Histamine H3 receptor antagonist | | |
| 0.075 | 0.065 | 0.075 | Opioid kappa receptor antagonist | | |
| 0.062 | 0.052 | 0.062 | Opioid mu receptor antagonist | | |
| 0.148 | 0.139 | 0.148 | Potassium channel (Voltage-sensitive) blocker | | |
| 0.088 | 0.079 | 0.088 | Electrolyte absorption antagonist | | |
| 0.021 | 0.012 | 0.021 | Apolipoprotein B inhibitor | | |
| 0.068 | 0.06 | 0.068 | Orexin receptor 1 antagonist | | |
| 0.055 | 0.048 | 0.055 | Acetylcholine M3 receptor antagonist | | |
| 0.023 | 0.017 | 0.023 | Aminopeptidase P inhibitor | | |
| 0.011 | 0.005 | 0.011 | Baculoviral IAP repeat-containing protein 2 inhibitor | | |
| 0.053 | 0.047 | 0.053 | Cathepsin L inhibitor | | |
| 0.029 | 0.023 | 0.029 | Potassium channel subfamily K member 3 blocker | | |
| 0.075 | 0.07 | 0.075 | Histamine antagonist | | |
| 0.018 | 0.014 | 0.018 | Complement factor D inhibitor | | |
| 0.038 | 0.034 | 0.038 | Oxytocin agonist | | |
| 0.026 | 0.023 | 0.026 | HCV NS5A inhibitor | | |
| 0.057 | 0.055 | 0.057 | Dopamine agonist | | |
| 0.084 | 0.083 | 0.084 | Toll-Like receptor 3 antagonist | | |
| 0.04 | 0.039 | 0.04 | Dihydroorotase inhibitor | | |
| 0.069 | 0.068 | 0.069 | Vanilloid 4 agonist | | |